Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
We report on the outcomes of 53 patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia secondary to MDS, autografted in first complete remission. Five (9.4%) died from the procedure whereas hematological reconstitution occurred in all the remaining patients. Forty patients (75%) relapsed, with 87.5% of the relapses occurring within 2 years of the autologous transplant. With a median follow-up of 6.2 years, the median actuarial disease-free survival and overall survival were 8 and 17 months after autograft, respectively. Karyotype was the only prognostic factor for disease-free and overall survival. The eight survivors (15%), including two patients with unfavorable or intermediate karyotype, remained in first complete remission 50+ to 119+ months after transplantation and are probably cured.
Service d'Hématologie, Pavillon E, CHU, Hôpital Edouard Herriot, 5, place d'Arsonval, 69437 Lyon Cédex 03, France.
Sophie
S
Ducastelle
Lionel
L
Adès
Claude
C
Gardin
Hervé
H
Dombret
Thomas
T
Prébet
Eric
E
Deconinck
Bernard
B
Rio
Xavier
X
Thomas
Stephan
S
Debotton
Agnès
A
Guerci
Nicole
N
Gratecos
Aspasia
A
Stamatoullas
Nathalie
N
Fegueux
François
F
Dreyfus
Pierre
P
Fenaux
Eric
E
Wattel
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D033581:Stem Cell Transplantation; D015996:Survival Rate; D013995:Time; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents